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2 ~ Abstract: 
o\1 
,{fl Approximately 30 million people are affected by diabetes in the United States alone. 
Insulin used to treat diabetics can lead to a variety of deleterious effects, including 
memory loss, during episodes of low blood glucose, or hypoglycemia. The branched 
polymer of glucose, known as glycogen, is a proposed neuroprotectant against the 
neurodegenerate affects of hypoglycemia, possibly serving as an alternate energy 
source to neurons during times of low blood glucose levels. Due to neurons inability 
to store glycogen as a glucose reservoir, glycogen within astrocytes undergoes 
glycogenolosis to form the transportable substrate lactate, which will then be 
shuttled to the neurons. Lactate is then converted back to pyruvate within the 
neuron and undergoes the TCA cycle, generating energy for the neuron. To test the 
hypothesis of glycogen acting as a neuroprotectant during times of hypoglycemia, 
mice with and without brain glycogen were exercised using a motor memory 
instrument, rotarod, while in various glycemic states. Brain tissue was then 
harvested and s'ubjected to a western blot in order to analyze the expression of 
memory proteins. When compared to wildtype, mice lacking brain glycogen have 
impaired memory formation during periods of hypoglycemia. Therefore, it is 
expected that mice lacking brain glycogen will have lower expression of memory 
proteins. Mice lacking brain glycogen also have higher levels of lactate within the 
blood following rotarod exercise, suggesting lactate's role as a compensatory 
mechanism for memory formation when blood glucose is unavailable. 
Acknowledgments 
I would like to thank Dr. Bartholomew Pederson for his continued patience and 
assistance in this thesis project. He has served as an upstanding mentor and helping 
hand through my years in research. 
I would like to thank my lab partners Dan, Cody, Hannah, Cale, Brittany, Logan as 
well as the lab technician Justin Crowder for their continued support of the project. I 
would also like to that Staci Weaver for all the rotarod work she completed while in 
the lab. 
Process Analysis Essay: 
This thesis project took place over a span of 6 semes~ers, beginning in the spring 
of my sophomore year. The prevalence of the research to diabetes and its potential to 
assist in identifYing an effective therapy to treat diabetic patients that doesn't expose 
them to cognitive impairment associated recurrent hypoglycemia motivated me 
throughout the project. The brains main source of energy is glucose, thus a polymer of 
glucose, known as glycogen, potentially serves as an emergency energy store when 
glucose is not readily available to the brain during times of hypoglycemia. Glycogen 
metabolism and its potential role as a neuroprotectant against hypoglycemic memory loss 
is the central focus ofthis thesis and other experimental work conducted' in this lab. 
Two mouse models were utilized in this lab, one null of any brain glycogen and 
one with normal levels of brain glycogen, in order to determine the role glycogen plays in 
memory formation. Based on previous reports that glycogen plays a role in memory 
formation during times of hypoglycemia, we hypothesized that mice lacking brain 
glycogen would have impaired memory formation when compared to WT mice. In order 
to test this hypothesis, mice were subjected to a single treadmill rotarod machine over a 
course of four trials. During trials 2 and 3 hypoglycemia was induced using insulin in 
order to evaluate memory formation during insulin-induced hypoglycemia. The results of 
this experiment supported our hypothesis, indicating that glycogen does in fact play a 
neuroprotective role in memory formation during times ofhypoglycemia. 
The thesis project required hours of work to be set-aside during the week to use 
the rotarod machine and conduct bench work, as well as years of study to reach an 
appropriate sample size. Even prior to the experimental procedures, hours of reading 
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were required in order to fully understand glycogen metabolism and its possible role in 
diabetes therapy. At times the experimental procedure would be compromised or 
experimental errors would occur while performing bench work, thus compelling me to 
preserve through the tough times in order to reach my final goal. The project instilled in 
me a patience and appreciation for research previously absent. The entirety of the 
experiment consisted of increased levels of stress, but adjusting to this stress not only 
assisted me in the lab but also helped me preserve through the stress associated with 
things outside of the lab such as academia. The patience I accumulated while working in 
the lab helped me take challenges such as dental school applications/interviews or final 
exams head on. I found I was better able to deal with problems in everyday life due to the 
values instilled in me while in the lab. 
Aside from patience and perseverance, the thesis project required a lot of 
teamwork and coordination with other members of the lab. The teamwork and leadership 
skills I inherited throughout my time working on my thesis are essential to the success I 
am able to obtain outside of the lab. All in all, the entire project not only resulted in a 
final thesis, but in the growth of my personal character. It is my hope and belief that the 
results from my thesis project will add to the diabetic research communities knowledge 
on the role of glycogen metabolism during times of hypoglycemia, eventually leading to 
an alternative therapy to insulin treatment. On a smaller scale, the hard work I put into 
this lab will motivate future undergraduate students to take on a role in research, 
whatever the field may be. In Dr. Pederson's lab in particular, it is my hope that my 
leadership skills assisted many of the younger students in lab protocol and etiquette. 
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Introduction 
Diabetes mellitus, characterized by recurrent exposure to hyperglycemia 
consequential of insulin secretion defects or insulin resistance (2006), affects 
approximately 30 million Americans and is currently the ih leading cause of death in the 
U.S (2012). lfleft untreated, diabetes results in long-term exposure to hyperglycemia 
leading to organ failure in a variety of vital organs, including the kidneys and eyes, and 
impaired cognitive function (Reijmer 2010). Diabetes mellitus can manifest in one of two 
forms, type I or type II diabetes. Type I diabetes, most commonly diagnosed in children, 
is characterized by a complete deficiency of insulin production by pancreatic beta cells. 
Type II diabetes, the more prevalent of the two forms, is caused by a resistance to the 
insulin naturally produced in the body. Normal blood glucose levels, known as 
euglycemia, occur at approximately 4.5 mmol/L (Reijmer 2010), however, the 
hyperglycemia consequential of diabetes results in blood glucose levels at or above 11 
mmol/L. Insulin therapy is a common treatment method utilized to return blood glucose 
to normal levels (Herzog 2011). 
Insulin administration often times results in abnormally low blood glucose levels, 
known as hypoglycemia, and is thus the principle obstruction to maintaining normal 
glucose metabolism and blood glucose levels (Amaral2012). Glucose is the central fuel 
source to the brain, thus brain activity is extremely reliant upon cerebral glucose 
metabolism (Amaral2012). When blood glucose drops to hypoglycemic levels, 
2.0mmol/L, glucose in the brain is almost entirely depleted due to the elevated glucose 
metabolic rates needed to produce the energy necessary to support neuronal function 
(Herzog 2011). Low brain glucose levels have been shown to have a neurodegenerate 
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effect leading to impaired cognitive function and memory formation (Suzuki 2011 ). On 
average, diabetic patients utilizing insulin therapy to treat their hyperglycemia, 
experience mild hypoglycemia about twice a week (Bolo). Severe hypoglycemia can lead 
to seizures, neuronal cell death, and comas if consistently induced. Due to the prevalence 
of hypoglycemia and the resulting cognitive impairment, identifying alternative therapies 
that affectively limit exposure to hyperglycemia without inducing hypoglycemia is of 
paramount concern (Herzog 2011). 
Glycogen, the branched polysaccharide utilized by humans to store and utilize the 
brains main energy source glucose (Figure 1 ), has been proposed to play a possible 
neuroprotective role during times of hypoglycemia. Glycogen synthesis, glycogenesis, 
results from the enzyme glycogen synthase generating alpha 1-4 bondages between 
glucose monomers and only occurs in astrocytes (Suzuki 2011). Neurons inability to 
synthesize and store glycogen indicates an essential supportive role of astrocytes in 
neuronal cell function (Suzuki 2011 ). Stored glycogen within the astrocytes can be 
degraded by glycogen phosphorylase, eventually yielding lactate that can be shuttled 
across monocarboxylate transporters (MCTs) into neurons where it can be utilized to 
generate the energy necessary for neuronal function (figure 2) (Suzuki 2011). It has been 
shown that this astrocytic glycogen metabolization is required for long-term memory 
formation and neuronal cell functions (Suzuki 2011 ). Ana Amaral proposed in her 
hypoglycemia review that the interconnected neuronal-astrocyte metabolism results in a 
redox coupling reaction that allows astrocytes and neurons to differentially select either 
lactate or glucose to use as an energy source, implying lactate and other glycogenolysis 
substrates act as alternative energy sources capable of rescuing memory formation during 
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times of hypoglycemia. The proposed neuroprotective role of glycogen makes it the 
central focus of this lab and the experiments completed within this lab. 
Of particular interest is the effect hypoglycemia has on formation of motor 
memory, or the process of encoding a complex movement sequences within the brain 
(Chagniel2013). Expression of motor memory proteins such as Creb, pCreb, and Arc 
has been shown to increase following exposure to motor memory tests (Chagniel 2013 
and Min 2014), therefore analyzing protein expression in brains of mice containing 
differing levels of brain glycogen could help reveal whether glycogen plays a 
neuroprotective role. For this project, motor protein KIF17 was designated to evaluate 
memory formation. To our knowledge, KIF17 has yet to be directly correlated to motor 
memory formation, however it has been shown that the protein is interconnected to Creb 
and pCreb phosphorylation cascades (Roberson 2008). Mice were trained for motor skill 
of running using a single treadmill rotarod machine in order to measure motor memory 
formation. Motor learning occurs in both fast and slow learning stages within the 
cerebellum and hippocampus of the brain (Doyon 2009). Accordingly, mice were 
subjected to the rotarod treadmill at two differing intensities, the first being an 
accelerating speed from 3-30 RPM and the second a consistent speed of 28RPM. To 
interpret whether or not KIF17 expression is directly affected by motor memory 
formation, different regions of the brain (hippocampus, cerebellum, and cortex) were 
harvested following rotarod exposure and subjected to a western blot analysis. 
We hypothesized that glycogen plays a neuroprotective role in motor memory 
formation during times of hypoglycemia, thus mice containing brain glycogen would 
have increased latency on the rotarod and show increased expression of memory proteins. 
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Genetically altered mice null for brain glycogen were compared to WT mice in order to 
examine glycogen's neuroprotective role. The single treadmill rotarod was utilized to test 
the formation of motor memory. Mice were subjected to four trials over a course of eight 
days and hypoglycemia was induced during trials 2 and 3 to evaluate the cognitive effects 
of low brain glucose. On the last trial of rotarod, WT mice previously treated with insulin 
were able to sustain balance on the rotarod for a time similar to those treated with saline, 
where as insulin treated mice lacking brain glycogen experienced significantly shorter 
latency on the treadmill machine. To further support glycogens neuroprotective role, 
percent improvement across the four trials was calculated and once again WT mice had 
significantly higher improvement rates than mice lacking brain glycogen, suggesting 
glycogen assisted in memory formation during times of hypoglycemia. Western blotting 
ofhippocampal and cerebellum brain tissue indicated expression ofKIF17 at 170kD, 
following exposure to the rotarod machine. However, the western provided no conclusive 
evidence as to whether or not WT mice had higher KIF17 expression levels than mice 
lacking brain glycogen. 
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Figure 1: Utilization of glucose as energy source once entering brain cells. Glucose 
enters neurons and astrocytes through GLUT3 and GLUTl transporters respectively and 
then enters glycolysis, generating both ATP and pyruvate. In order to generate ATP 
pyruvate undergoes the TCA cycle, followed by oxidative phosphorylation. 
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Figure 2: Glycogen metabolism in the astrocytes supplies neurons with an alternate 
energy source when blood glucose levels are low. In astrocytes, glucose entering the 
brain can be used to generate A TP or stored as glycogen. When blood glucose levels are 
low, glycogen can be metabolized into lactate which can be shuttled from astrocytes into 
neurons where it can be converted back into pyruvate to generate A TP. 
MATERIALS AND METHODS 
Generation of MGSKO/GSL30 mouse line 
Lexicon Genetics Incorporated provided mice heterozygous for the glycogen 
synthase gene GYSJ (Pederson 2004). Embryonic stem (ES) cells from the Lexicon 
Genetics Omnibank library of gene trapped ES cells were infected with VICTR25, a 
retroviral gene trap vector, upstream of exon 12 on the GYSJ gene (Pederson 2004). 
Embryonic stem cells containing a normal karyotype of the disrupted GYSJ gene were 
then injected into C57BL/6J blastocysts and these blastocysts implanted into 
pseudopregnant female mice. Pups resulting from the C57BL/6J blastocyst implantation 
were crossed with C57BL/6J X 129/SvJ mice and gene disruption was confirmed by 
Southern Analysis (Pederson 2004). These mice were then mated to generate a mouse 
model null ofthe GYSJ gene, referred to as muscle glycogen synthase knockout 
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(MGSKO). Pups homozygous for GYSJ disruption (GYST1-) were affected by both 
venous and pulmonary congestion, resulting in just a 10% survival rate (Pederson 2004). 
Due to low survival rate, a more viable mouse model null for glycogen synthase 
in the central nervous system was needed. To accomplish this, MGSKO mice were 
crossed with mice expressing increased levels of the glycogen synthase protein in the 
muscle, denoted as GSL30 (Manchester 1996). GSL30 mice contain a creatine kinase 
gene promoter that directs muscle specific expression of GYSI, causing an 
overexpression of glycogen synthase in the skeletal muscles, but no increase in the brain 
(Manchester 1996). These GSL30 mice were crossed with GYST1-mice, resulting in GYS 
+!-mice with transgene expression (Pederson 2004). GYSI+I-mice with transgene 
expression were mated with other GYSJ+I- mice in order to generate mice null of any 
endogenous glycogen synthase, but overexpressed glycogen synthase in the muscle, 
GYSrl-!tg. The result of this cross was a viable mouse line containing no glycogen in the 
central nervous system (MGSKO/GSL30). A multiplex as well as a uniplex PCR 
reaction was used to confirm the genotype of the MGSKO/GSL30 line, using toe 
clippings from each experimental mouse. 
Mouse Husbandry 
Mice were kept in a temperature and humidity controlled room with a 12-hour 
light and dark cycle. Mice had access to food and water at all times unless stated 
otherwise in procedures requiring the mice to be fasted over night. The Ball State 
University Animal Care and Use Committee approved all procedures and husbandry. 
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Experimental mice 
Male mice of approximately three months of age, from the MGSKO/GSL30 line 
were used during this experiment. Genotypes GYSJ+I+ (WT) and GYSJ -l-l tg were used to 
test glycogen's proposed ability to act as a neuroprotective agent. 
MOTOR MEMORY EXPERIMENTAL PROCEDURES 
Rotarod-fed state motor learning 
Before subjecting the mice to rotarod during times of hypoglycemia, mice were 
subjected to the rotarod (figure 3) while in the fed state, acting as positive control. The 
mice were subjected to four experimental trials on the rotarod over eight separate days. 
Latency, the amount of time spent on the rotarod before falling, was measured during 
each trial. Latency measurement was concluded in one of three ways: the mouse rotated 
in a full circle around the rotarod, the mouse fell from the rotarod, or the mouse reached 
the maximum allotted time limit. An increase in latency over the four trials would 
indicate motor learning is occurring over the course of the eight days. 
Mice were subjected to four trials consisting of two differing speed settings 
during each experimental day. During trial 1 (Day 1 ), the mouse was placed on the 
rotarod subjected to an initial speed of3.0 RPM that would accelerate to as many as 30 
RPM. The amount of time spent on the rotarod was measured up to a maximum of five 
minutes. The mouse was then taken off the rotarod and allowed to rest for 30 seconds 
before being placed back on the rotarod and subjected to a constant speed of 28 RPM for 
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a maximum of 90 seconds. This condition was repeated twice more with 30 sec of rest 
between each, and latency was measured each time. In between individual mice, the 
rotarod was wiped down using 66% ethanol in order to eliminate any odor from previous 
mice that may affect future mice's performance. The same protocol was used during trial 
2 (day 2), trial 3 (day 6), and trial 4 (day 8). 
Rotarod - hypoglycemic motor learning 
Mice were subjected to either saline or insulin injections prior to rotarod in order 
to assess glycogen's neuroprotective role in motor learning during times of 
hypoglycemia. This motor memory test took place using a single rotation rotarod 
treadmill (Med Associates Inc ENV -567M) and mice were subjected to four trials 
occurring over a course of eight separate days. During each trial final latency 
measurement was concluded as described above. 
For triall (day 1) mice were moved into the experimental room containing the 
rotarod 30 minutes prior to exposure to the rotarod (~1:30pm). Four mice, two GYSJ +I+ 
and two GYSJ -I-Itg were brought into the room to undergo the rotarod experiment. One 
mouse would be exposed to the rotarod at a time and ~15 minutes was placed between 
the end of one mouse's attempts and the beginning of the other's. Blood glucose was 
measured from tail vein, as described below, prior to the rotarod experiment and the tail 
was cauterized to prevent further bleeding. Each mouse underwent 4 attempts on the 
rotarod with ~30 seconds between attempts. During attempt one the rotarod rotates at an 
accelerating speed from 3.0RPM to 30RPM for a maximum of five minutes. Following 
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the first attempt, the mouse would then undergo three attempts on the rotarod spinning at 
a constant speed of 28 RPM for a maximum of 90 seconds. 
The night prior to trials 2 (day 2) and 3 (day 6), mice were fasted at ~5pm. On the 
day of the experimental trial mice were moved into the experimental room half an hour 
prior to injections (~12:30pm). Each mouse was weighed to the nearest 0.1g and a 
syringe would be prepared for each mouse containing either saline or insulin. One WT 
mouse would receive insulin, while the other would receive saline and the same 
parameters were in place for GYSJ -I-Irg mice. The first mouse had its blood glucose 
measured, followed by an intraperitoneal injection of the appropriate dose, as indicated 
below, at ~ 1 pm. Fifteen minutes was left between each injection, thus mouse 1 received 
an injection at 1 pm, mouse 2 at 1:15pm, mouse 3 at 1:30pm, and mouse 4 at 1:45pm. 
Following the initial injection blood glucose was measured 30 minutes following the 
injection, 60 minutes following the injection, and immediately after the mouse completed 
the final attempt on the rotarod. Sixty minutes after injection, mice were then exposed to 
the rotarod under the same conditions as used in day 1 (a single attempt at an accelerating 
speed of3.0RPM to 30RPM, followed by three attempts at a constant speed of28RPM). 
For trial 4 (day 8) mice were moved into the experimental room half an hour prior 
to the experiment (~1:30pm) and the same experimental procedure used during trial 1 
(day 1) was followed. 
Hypoglycemia induction 
The night prior to rotarod experiments requiring induced hypoglycemia, mice 
were fasted starting at 5pm. To ensure the mice had no access to food, the mice were 
12 
placed in a new cage with fresh bedding and the food container was emptied. The 
following day insulin preparation began at 12:30, approximately half an hour before the 
first injection. Each mouse used for the experiment was placed in a balance and measured 
to the nearest 0.1g. Insulin, 70/30 Hurnulin Insulin (Eli Lilly), was diluted with 0.9% 
saline such that that administration of 5 f..ll/g body weight resulted in a dose of 0.6U/kg for 
WT mice and 1.0 U/kg for GYSJ-I-Itg mice. Saline (0.9%) was administered at 5f..ll/g body 
weight for all mice, regardless of genotype, not undergoing hypoglycemia. Mice were 
administered either insulin or saline intraperitoenally, based on treatment group, one hour 
before they were subjected to the rotarod attempts. Following rotarod attempts the mice 
were put back into their horne cage andre-fed. 
Blood glucose measurements 
Blood glucose was monitored in each mouse prior to injection, 30 minutes 
following the injection, 60 minutes following the injection, and following the final 
rotarod attrnpt. Blood glucose was monitored using HernoCue Glucose 201 microcuvettes 
and a HernoCue Glucose 201 glucometer. Each mouse had a small portion of its tailed 
clipped using dissection scissors. The tail was then milked to extract approximately 5 f..ll 
of blood that would then be loaded into a HernoCue Glucose 201 rnicrocuvette. This 
rnicrocuvette was then wiped with a kimwipe (KIMTECH) to remove any excess blood 
and placed in the glucorneter to be read. 
Lactate measurements 
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Lactate levels in the blood were measured prior to the rotarod trial (60 minutes 
after injection) and following the rotarod trial. In order to measure lactate, LactatePlus 
strips (Nova Biomedical40813) were inserted into a LactatePlus lactate reader (Nova 
Biomedical 40828). Similar to glucose readings, the tail was milked for blood and this 
blood was loaded into the lactate strips and placed into LactatePlus reader. Following the 
reading, a silver nitrate stick was used to cauterize the tip of the tail and prevent further 
bleeding. 
MOTOR MEMORY PROTEIN ANALYSIS 
Hippocampus removal 
In order to investigate the expression of proteins involved in motor memory 
formation, the brain from each experimental mouse was harvested approximately 24 
hours following the final rotarod trial. To harvest the brains, mice were decapitated and 
the head placed in diluted lx phosphate buffered saline (PBS) that is formulated to mimic 
physiological serum conditions. The brain was then dissected using dissection scissors 
and blunted forceps preventing damage to the tissue. Once removed, different regions of 
the brain (hippocampus, cerebellum, cortex) were dissected in order to evaluate motor 
memory protein expression in differing areas of the brain. To dissect the cerebellum, a 
scalpel was used to detach the cerebellum from the cortex of the brain. Next the cortex 
was cut in half using a scalpel and the tissue covering the hippocampus was peeled back 
and the hippocampus was removed using a blunted surgical spatula (figure 4). Each 
region of the brain was placed into a separate liquid nitrogen-filled scintillation tube 
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following dissection. Brain tissue was then powdered using a tissue pulverizer and stored 
at -80°C. 
Tissue Homogenation 
In order to evaluate motor memory protein expression in the brain, tissue was 
homogenized to lyse and isolate the proteins from the cell membrane. Brain tissue was 
homogenized utilizing a method described by Roberson et al. The isolated protein was 
quantified using the Bradford assay to determine protein concentration in each sample for 
ensuing western blot analysis. 
Brain samples containing hippocampus, cortex, and cerebellum brain tissue were 
moved from -80°C freezer and immediately placed into liquid nitrogen. Tissue from each 
sample was weighed ( 40-50mg) and relocated to nitrogen-cooled microfuge tubes. 
Samples were then thawed on ice for I minute and homogenized on ice for 30 seconds, in 
10 volumes (ie.400~1/40 mg) of homogenization buffer (0.2M NaCl, 0.05M Tris, 
2mMNaF, 2.5mM EDTA (sigma E5134), DTT (1M), Na2,P20 7 , protease inhibitor (sigma 
P8340), 1 OO~M sodium orthovanadate) using a tissue tearor at its maximum speed setting 
(Biospec Products, 985370-04) After all samples were homogenized, tubes were 
centrifuged for 15 minutes at 16,000xg at 4 °C. Once centrifuged, 50~1 of each sample 
was ali quoted to fresh centrifuge tubes and stored at 4 oc for future Bradford assays. 
Another 200~1 of supernatant from each centrifuged sample was placed in a separate, 
fresh centrifuge tube, mixed with 5X SDS-PAGE loading buffer with BME (beta 
mercaptoethanol Sigma M7522) and placed on ice. Samples were then heated at 70°C for 
10 minutes and then stored at -20°C for subsequent western blotting. 
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Bradford assay 
Following homogenization, a Bradford assay was preformed to determine protein 
concentrations of samples. Based on protein concentrations, appropriate amounts of 
protein were calculated to ensure equal protein loading for Western blotting. 
Samples set aside for a Bradford assay during tissue homogenization were taken 
from 4°C storage and maintained on ice. BSA (2mg/ml, ThermoScientific PA196779) 
solutions of differing dilutions (0%, 0.05%, 0.1 %, 0.25%, 0.5%) were prepared in order 
to compare protein concentrations of samples to a standard curve. BSA solutions and 
experimental samples, at a 1:10 dilution of sample to water, were loaded into 96 well 
plate and mixed with Thermo Coomassie Bradford reagent (ThermoScientific 1856209). 
The plate was then mixed on a microplate genie and read on a microplate reader (ELx800 
UV BioTek Instruments) to quantify protein concentration using spectrophotometry. 
Western Blotting 
Samples set aside for western blot analysis were removed from -20°C storage and 
set on ice to thaw. While samples were thawing, agarose SDS-PAGE gels were prepared 
in two steps. First a 10% separating gel was constructed (acrylamide (BioRad 37 5:1), 
1.5M Tris-Cl pH 8.8 with SDS, ELIX water, ammonium persulfate, TEMED 
(BioChemika 87689)) and poured between two electrophoresis plates. The stacking gel 
sat for 45 minutes at room temperature to polymerize. Once polymerized, 5% stacking 
gel (acrylamide (BioRad 37 5:1), 0.5M Tris-Cl pH 6.8 with SDS, ELIX water, 
ammonium persulfate, TEMED (BioChemika 87689)) was poured over the separating 
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gel, a comb was inserted in the solution creating wells for samples and the gel was 
allowed to polymerize at room temperature for 45 minutes. 
Once the gel was fully polymerized, 1X running buffer (5X Tris/glycine/SDS 
running buffer and Elix) was poured between the plates and electrophoresis tank. 
Agarose gel (2% agarose solution) prevented leakage of running buffer between the 
plates. The initial well in the gel was filled with 5J..i.l ofThermoScientific PageRuler pre-
stained molecular weight ladder (ThermoScientific 26616). Remaining wells were then 
filled with 30J..i.l of brain tissue samples in 1X SDS loading buffer. Electrodes were then 
hooked up to the electrophoresis apparatus and the samples were run at 200V for one 
hour. Upon completion the plates of the cassette were gently separated and a transfer 
sandwich was prepared. The sandwich was layered in the following order: scotch brite 
pad, 3MM paper, gel, nitrocellulose membrane (Amersham Protran 0.45J..lm NC), 3MM 
paper, scotch brite pad. The sandwich was placed into the transfer apparatus (BioRad) 
and run at 100V for 90 minutes in transfer buffer (Trizma base (Sigma T1503-
1KG)/Glycine (Gold Biotechnology G-630-1)/methanol (VWR analytical BDH2018-
5GLP)/elix) 
Following the transfer, the sandwich was dismantled and the membrane removed. 
The membrane was then stained in 0.1% Ponceau stain (ponceau (Sigma 094K3651), 
glacial acetic acid (Sigma SHBC9403V), type 2 water) for one minute in order to 
preview total protein on the membrane (figure 5). Ponceau stain was removed and the 
membrane was then rinsed in type 1 water to remove excess stain. Following imaging of 
the membrane, the membrane was cut in half to blot with antibodies against loading 
control and experimental protein of interest separately. The membrane was then washed 
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in 1XTBS/ 0.1% tween (5XTBS (200mM Tris/500mM NaCl pH 7.5), type 2 water, 
tween (Sigma SLBH5836V) until pink stain on membrane was completely gone. 
Following staining, 1XTBS/Tween/3% milk blocking solution was prepared. 
Membranes were submerged in the blocking solution and blocked with rocking at room 
temperature for 2 hours. Blocking solution was discarded following the hour block and 
antibodies were prepared. KIF17 (Sigma K3638) primary antibody was diluted (1 :600) 
in 1XTBS/0.1% Tween/ 3% skim milk (LabScientific M0841) and GAPDH (Sigma 
NB300) primary antibody was diluted (1 :5000 in 1XTBS/ 0.1% Tween/ 2% milk). 
Membranes containing the protein of interest (KIF 1 7) were submerged in KIF 17 
antibody, while membranes containing the loading control protein (GAPDH) were 
submerged in GAPDH diluted antibody. These membranes were then rocked with the 
primary antibodies overnight at 4°C. 
Secondary Antibodies were prepared the following day for both KIF17 (1 :5000 
dilution of goat anti-rabbit IgG (Sigma A6154) inlXTBS/0.1 %Tween/3% milk and for 
GAPDH (1 :2000 dilution of anti-mouse antibody (Novus HAF007) in 
1XTBS/0.1% Tween/3%milk). Secondary antibodies were poured into reagent tubes that 
were then secured into the appropriate position on the Blotbot (NextAdvance Freedom 
Rocker BlotBot 240). Primary antibodies were then removed from the membranes and 
membranes were placed into appropriate trays in BlotBot. The BlotBot was programmed 
to complete the blot with the following steps: 
• 
• 
Wash in 1 XTB S/0 .1% Tween two separate times for 1 0 seconds each 
Wash in 1XTBS/0.1%Tween three separate times for 10 minutes each 
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• 
• 
• 
• 
Rock in secondary antibody at room temperature for 1 hour 
Discard secondary antibody solution 
Wash in 1XTBS/O.l%Tween two separate times for 10 seconds each 
Wash in lXTBS/0.1 %Tween three separate times for 10 minutes each 
Following blotting in the BlotBot, ECL reagent (Supersignal West Pico-
Thermoscientific #34079) was prepared mixing 1.25 mL of supersignal west stable 
peroxide solution and 1.25mL of supersignal west pico luminol/enhancer solution. 
Membranes were removed from blotting tray, drained of solution by blotting on kimwipe, 
and placed protein side up in clean dish. A transfer pipet was then used to add ECL 
solution directly to the surface of each membrane and allowed to incubate for ~5 minutes. 
The membrane was then drained of the ECL reagent and blotted to remove remaining 
liquid. The dried membrane was then wrapped in plastic wrap (Glad ClingWrap) and 
molecular weight markers on ladder were marked using sharpie marker. Wrapped 
membranes were placed on Kodak imager (Kodak DigitalScience Image Station 440) to 
be imaged using Kodak lD 3.6 software. The membranes were previewed first to ensure 
"image overlay" between the preview and ECL would be accurate. Once preview of the 
membrane was captured, the imager was closed and the ECL membrane exposed for an 
appropriate amount oftime. Using Kodak lD 3.6 software the final images were adjusted 
using differing contrasts to provide best quality available. 
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Figure 3: Single treadmill rotarod machine was utilized in order to measure motor 
memory formation. Mice underwent the rotarod over a series of four trials in order to 
measure their ability to form memory of new motor skills. The speed of the treadmill was 
set to either level 7 (3-30RPM) or level 3 (28RPM) in order to expose mice to differing 
speeds on the rotarod. 
Figure 4: Brain tissue was dissected from mice that previously underwent rotarod in 
order to track protein expression using a western blot analysis. The brain cortex, 
cerebellum, and hippocampus were all dissected from the brain and placed in liquid 
nitrogen to conserve the metabolites within the tissue. The tissue was then powdered, 
homogenized, and then analyzed using a western blot. 
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Figure 5: Membranes are stained using ponceau stain to show total protein 
expression. Following transfer from gel onto a membrane, proteins were stained using a 
ponceau stain to give a preliminary indication as to whether or not equal concentrations 
of protein were loaded into each lane. 
RESULTS 
Rotarod- Fed State Motor Learning 
To determine if brain glycogen is important for motor memory formation, a 
former student in Dr. Pederson' s laboratory subjected mice with or without brain 
glycogen to the single rotation rotarod treadmill in the fed state. Mice were exposed to 
two alternative speeds while on the rotarod and motor memory was traced for each speed 
setting using latency measurements, or time to fall. Mice were first subjected to the 
rotarod with an accelerating speed from 3.0RPM up to 30RPM (level 7). Following one 
attempt at level 7, mice were then subjected to three consecutive attempts at a constant 
speed of28RPM (level 3). 
Latency on rotarod in f ed state on rotarod set to level 7 
21 
Latency was measured in both GYSJ +!+ (WT) and GYSJ -I-Itg mice over a course of 
four trials (figure 6). There was no significant difference in latency to fall between WT 
and G YS 1 -l-ltg for all trials (trials 1-4). Percent improvement in latency from trial 1 to trial 
4 while in the fed state was also insignificant between WT and GYSJ-I-Itg. 
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Figure (6): Latency on rotarod set to level 7 increased consistently over four 
consecutive trials across in both WT and GYSJ-I-Itg mice in the fed state. Latency was 
measured in both GYSJ -I-!tg (n=29) and WT (n=21) mice. Mice were in the fed state 
through all four trials. There was no difference in percent improvement from trial 1 to 
trial 4 between WT and GYSJ-I-Itg. Significance was determined using a non-parametric t-
test. 
Latency on rotarod in fed state on rotarod set to level 3 
Latency was measured in both GYSJ +!+ (WT) and GYSJ-I-Itg mice over a course of 
four trials (figure 7). There was no significant difference in latency to fall between WT 
and GYSJ-I-Itg for trials 1,2, and 4. During trial 3 GYSJ-I-Itg mice displayed a shorter 
latency time compared to WT mice (P<0.0001). Percent improvement in latency from 
trial 1 to trial4 while in the fed state was also insignificant between WT and GYSJ-I-Itg. 
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Figure (7): Latency on rotarod set to leve13 increased consistently across genotypes 
over four consecutive trials in both WT and GYSJ-I-Itg in the fed state. Latency was 
measured in both GYSJ-I-Itg and WT mice. N was between 21-29 for each group. Mice 
were in the fed state through all four trials. There was no difference in percent 
improvement from trial 1 to trial4 between WT and GYSJ-I-Itg. Significance was 
determined using a non-parametric t-test. 
Rotarod- Hypoglycemic Motor Learning 
Blood glucose levels 
My studies examined the affects of hypoglycemia on memory. To assess the 
effect of hypoglycemia on motor learning, mice were subjected to four trials on the single 
rotation rotarod treadmill over a course of eight days. Mice were in the fed state during 
trials 1 and 4 and in fasted state during trials 2 and 3. During trials 2 and 3 mice were 
injected with either insulin to induce hypoglycemia or the vehicle saline. Blood glucose 
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was measured just before and immediately following rotarod treatment during trials 1 and 
4. During trials 2 and 3 blood glucose was measured prior to injection, 30 minutes 
following injection, 60 minutes following injection, and immediately following rotarod. 
~lood glucose levels during trial 1 (day 1): 
Blood glucose was monitored in both WT and GYSI-I-Itg mice prior to and 
following rotarod assessment. There was no significant difference in blood glucose levels 
between WT and GYSJ -1-!'g mice either prior to or following rotarod assessment (Figure 
8). Post-rotarod blood glucose levels were significantly higher when compared to pre-
rotarod blood glucose levels in both genotypes of mice (P<O.Ol) (figure 8). On average, 
WT blood glucose levels were 13% higher following rotarod assessment when compared 
to pre-rotarod blood glucose, while GYSJ-I-Itg blood glucose levels were 16% higher 
following rotarod assessment compared to pre-rotarod blood glucose levels. 
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Figure (8): Blood glucose levels increased following rotarod assessment in both WT 
and GYSJ-I-Itg mice. Blood glucose was measured in both WT and GYSI-I-Itg mice prior 
to and immediately following exposure to the rotarod instrument. N=38-40 for each 
group. Significance was measured using a Newman-Keuls multiple comparison test 
within a one-way ANOV A. 
Blood glucose levels during trials 2 (day 2) and 3 (day 6): 
During trials 2 and 3, blood glucose was monitored in both WT and GYSJ-I-Itg 
mice prior to injection, 30 minutes following injection, 60 minutes following injection, 
and following rotarod assessment. During both trials 2 and 3, both WT insulin treated and 
GYSJ-I-Itg insulin treated groups had significantly lower blood glucose levels 30 minutes 
following injection, 60 minutes following injection, and immediately following rotarod 
assessment when compared to the vehicle treated groups (p<O.OOOl) (figure 9). 
Consistent in both trials 2 and 3, there was no significant different in WT and GYSJ-I-Itg 
blood glucose levels prior to and following rotarod assessment. On average insulin 
treated WT mice were at a blood glucose level of 54 mg/dl and insulin treated GYSJ-I-Itg 
were at an average blood glucose level of 55 mg/dl (figure 9). 
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Figure (9): Blood glucose levels were lowered to hypoglycemic levels (40-60mgldl) in 
insulin treated groups. Blood glucose levels were measured prior to injection, 30 
minutes following injection, 60 minutes following injection, and following rotarod 
assessment in both WT and GYSJ-I-Itgmice. N=38-40 for each group. Significance was 
measured using a Newman-Keuls multiple comparison test within a one-way ANOV A. 
Blood 
Blood glucose was monitored in both WT and GYSJ -I-Itg mice previously treated 
with vehicle during trial 4 prior to and following rotarod assessment. There was no 
difference in blood glucose levels between WT and GYSI-I-Itgblood glucose levels prior 
to rotarod assessment (figure 10). On average WT and GYSI -I-Itg mice experienced blood 
glucose levels of 198mg/dl and 211mg/dl (respectively) prior to rotarod assessment 
(figure 10). GYSJ-I-Itg mice had significantly higher blood glucose levels following 
rotarod assessment when compared to WT blood glucose levels following assessment 
(p<0.001) (figure 10). There was no difference in blood glucose levels following rotarod 
assessmentwhen compared to post assessment blood glucose in both WT and GYSI -I-Itg 
mice (figure 10). WT and GYSJ-/-/tgexperience average blood glucose levels of221mg/dl 
and 246mg/dl (respectively) following rotarod assessment (figure 1 0). 
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Blood 
Blood glucose was monitored in both WT and GYSJ-I-!tg mice previously treated 
with insulin during trial4 prior to and following rotarod assessment. There was no 
difference in blood glucose levels between WT and GYSJ-/-/tgblood glucose levels prior 
to rotarod assessment (figure 10). On average WT and GYSJ-I-!tg mice experienced blood 
glucose levels of 20 I mg/dl and 220mg/dl (respectively) following rotarod assessment 
(figure 10). GYSJ-I-!tg mice had significantly higher blood glucose levels following 
rotarod assessment when compared to WT blood glucose levels following assessment 
(p<O.OOI) (figure 10). On average GYSJ -I-Itg mice experienced higher blood glucose 
levels following rotarod assessment when compared to WT mice (p<0.01) (figure 10). 
WT and GYSJ-I-!tg mice experience average blood glucose levels of233mg/dl and 
249mg/dl (respectively) following rotarod assessment (figure 1 0). 
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Figure (10): Blood glucose levels were higher in GYSrt-ttg than WT mice following 
rotarod assessment. Blood glucose levels were monitored prior to rotarod exposure and 
immediately following assessment in both WT and GYSl-/-ttg mice. N=38-40 for each 
group. Significance was measured using a Newman-Keuls multiple comparison test 
within a one-way ANOV A. 
Blood lactate levels 
Blood lactate was measured in both WT and GYSJ-I-Itg prior to and following 
rotarod assessment in order to investigate compensatory mechanisms during motor 
learning. 
Blood lactate levels pre-rotarod assessment 
There was no significant different during trials 1 and 4 when comparing WT and 
GYSJ -I-Itg blood lactate prior to rotarod assessment (figure 11). During trial 2, there was 
no difference saline treated WT and GYSJ -l-ltg prior to rotarod assessment. However, 
during trial2 insulin treated GYSJ -I-Itg mice experienced higher blood lactate levels when 
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compared to WT mice (p<0.0001) (figure 11). During trial 3, GYSJ-I-Itg mice experienced 
significantly higher blood lactate levels than both insulin and saline treated WT mice 
(p<O.OS) (figure 11 ). 
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Figure (11): During trials 2 and 3, prior to rotarod exposure, blood lactate levels 
were higher in GYSl-/-/tg than WT mice. Blood lactate was measured prior to rotarod 
assessment across all four trials in both WT (n=S) and GYS 1-/-/tg (n=S). A non-parametric 
t-test was used to evaluate signifigance in blood lactate levels between the two genotypes. 
Blood lactate levels post-rotarod assessment 
Consistent throughout all four trials, blood lactate levels were higher in GYSJ -I-Itg 
mice than both insulin and saline treated WT mice following rotarod assessment. 
(p<O.OS) (figure 12). 
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Figure (12): Consistent throughout all four trials, following rotarod assessment, 
blood lactate levels were higher in GYSl-/-/tg than WT mice. Blood lactate was 
measured immediately following rotarod assessment across all four trials in both WT 
(n=5) and GYSrt-/tg (n=5). A non-parametric t-test was used to evaluate signifigance in 
blood lactate levels between the two genotypes. 
Blood lactate levels pre-rotarod vs. post-rotarod 
Consistent throughout all four trials, blood lactate levels were unchanged between 
pre and post rotarod in WT insulin treated mice, WT saline treated mice, and GYSJ-I-Itg 
saline treated mice (figure 13). During trials 1, 3, and 4 blood lactate levels were 
significantly higher in insulin treated GYSJ-I-Itg mice post rotarod assessment when 
compared to blood glucose levels prior to rotarod (p<O.OS) (figure 13). Pre and post 
rotarod blood lactate levels showed no significant difference in insulin treated GYSJ-I-Itg 
mice (p=O.l)(figure 13). There is a nearly significant increase (p=0.08) in mean lactate 
levels following rotarod exercise across all four trials (table 1) 
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Triall Trial2 Trial3 Trial4 . 
WT-saline 0.91 0.4 0.85 0.48 
WT-insulin 1.08 0.58 0.85 1.03 
GYSl -1-/tg -saline 3.05 1.88 1.75 2.98 
GYSl -1-/tg -insulin 2.81 2.28 1.38 2.2 
Table 1: Blood lactate level increase following exposure to rota rod was significantly 
higher in GYSr/-/tg mice. Blood lactate was measure prior to rotarod exercise and 
immediately following exercise across all four trials in both WT (n=5) and GYS 1-/-/tg 
(n=5). Significance was measured using a Newman-Keuls multiple comparison test 
within a one-way ANOV A. 
Latency 
Latency to fall during level 7 (3-30RPM acceleration) rotarod 
During trial 1 (day 1) mice underwent the rotarod while in the fed state and no 
difference was observed in latency between WT and GYSI-I-Itg mice (figure 14). Mice 
were fasted prior to trial 2 (day 2) and received either an insulin or vehicle injection 60 
minutes prior to rotarod exposure. No difference in latency was observed between saline 
treated WT and GYSI -1-11g mice, nor was there difference in latency to fall between insulin 
treated WT and GYSJ -I-Itg mice (figure 14). GYSI-I-Itg mice treated with insulin had 
significantly shorter latency when compared to saline treated GYSI -!-ltg mice across trials 
2,3, and 4 (p<0.0001) (figure 14). Both WT and GYSI-I-Itg mice insulin treated mice 
experienced significantly lower latency to fall times during trials 2 and 3 when compared 
to saline treated WT mice (p<0.0001) (figure 14). During trial4, these insulin and saline 
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treated WT mice, showed no difference in latency (p=O.l433) (figure 14). Insulin treated 
GYSJ-I-Itg mice experienced a shorter latency during trial4 when compared to WT mice 
treated with insulin (p=O.Ol74) (figure 14). There was no differences observed in latency 
to fall times during trial4 between saline treated GYSJ-I-Itg mice and saline treated WT 
m1ce. 
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Figure (14): Saline treated mice consistently had longer latency across all four trials 
on level 7 (3-30RPM) of the rotarod; insulin treated WT mice had longer latency in 
trial4 when compared to GYSl-t-ttg. Both WT and GYSl-/-/tg mice underwent four trials 
over a course of eight days on the single rotation rotarod treadmill, n was 18-19 for each 
group. Mice were treated with either insulin to induce hypoglycemia or saline in order to 
analyze the effect of hypoglycemia on motor memory formation. Significance was 
measured using a Newman:-Keuls multiple comparison test within a one-way ANOV A. 
Latency to fall during level 3 (28RPM) rotarod 
During trial 1 (day 1) mice underwent the rotarod assessment while in the fed 
state and no difference was observed in latency between WT and GYSJ -I-Itg mice (figure 
15). Saline treated WT showed no significant difference in latency when compared to 
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saline treated GYSI-I-Itg mice in all trials (1-4). During both trials 2 and 3, there was no 
difference in latency to fall times between saline treated WT mice and saline treated 
GYSJ-I-Itg mice, nor was there difference observed between insulin treated WT mice and 
insulin treated GYSJ-I-Itg mice (figure 15). Insulin treated WT and GYSJ-I-Itg mice showed 
significantly lowered latency compared to saline treated WT and GYSI-I-Itg mice, 
respectively, during both trials 2 and 3 (p<O.OOOI) (figure 15). Insulin treated GYSJ-I-!tg 
mice had significantly lower latency than both insulin treated WT mice and saline treated 
GYSJ -I-Itg mice during trial4 (p<O.OOOl) (figure 15). Latency to fall times weren't 
different in insulin treated WT mice compared to saline treated WT mice during trial 4 
(p=0.1742) (figure 15). 
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Figure (15): Saline treated mice consistently had longer latency across all four trials 
on level 3 (28RPM) of the rotarod. There was no difference between WT saline, WT 
insulin, and GYSl-/-/tg saline treated mice during trial 4, insulin treated GYSl-t-ttg 
mice had significantly lower latency during trial 4 than the other 3 treatment 
groups. Both WT and GYS 1-/-/tg mice underwent four trials over a course of eight days 
on the single rotation rotarod treadmill, n was 18-19 for each group. Mice were treated 
with either insulin to induce hypoglycemia or saline in order to analyze the effect of 
hypoglycemia on motor memory formation. Significance was measured using a 
Newman-Keuls multiple comparison test within a one-way ANOV A. 
Western Blotting 
Hippocampal, cortex, and cerebellum tissue samples were subjected to western 
blot analysis in order to quantify memory protein KIF 17 expression following treatment 
to rotarod. Consistent with previous studies, KIF17 had a molecular weight of~ 170KD, 
but no definitive conclusions could be made concerning differential expression in 
differing brain regions or differential memory formation following hypoglycemia. 
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Discussion: 
This study was centered on the hypothesis that glycogen acts as a neuroprotective 
agent during times of hypoglycemia due to its ability to yield alternative energy sources 
to glucose, such as lactate and glutamate, following glycogenolysis. Glycogen stored in 
the astrocytes has been proposed to serve as a source of glucose substitutes which can be 
shuttled into neurons, which can be utilized to produce the energy needed for neuronal 
activity during times of hypoglycemia. The role of glycogen was investigated in the 
formation and recollection of motor memory in differing areas ofthe brain, including the 
hippocampus and cerebellum. 
Motor memory formation in the fed state 
In order to evaluate glycogen's role in memory formation during times of 
euglycemia, both WT and GYS 1-/-/tg were subjected to rotarod while in the fed state. 
There was no difference in improvement over the course of the four trials between the 
two genotypes (figure 6), suggesting both genotypes are equally capable of forming 
memory involving motor skills. These results support the conclusion that glycogen acts 
primarily as an emergency energy reserve (Suzuki 2011), rather than the primary fuel 
source needed to support neuronal activity during memory formation. This is in contrast 
to studies that indicate an important role for brain glycogen in associative memory 
(Newman, Suzuki, Duran). Thus it appears that different types of learning may have 
different requirements for brain glycogen utilization. Due to the ability of G YS 1-/-/tg mice 
to learn at an equal rate to WT mice during euglycemic conditions, it is hypothesized that 
differences in learning between the two genotypes, occurring in the hypoglycemic state, 
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is due to the utilization of glycogen reservoirs within the astrocytes of the brain. 
Therefore, we expect the mice lacking brain glycogen, GYSrt-ltg, will have decreased 
levels of motor memory formation during times of hypoglycemia when compared to WT 
m1ce. 
Motor memory formation during times of hypoglycemia 
Insulin induced hypoglycemia 
In order to investigate glycogen's possible role as a neuroprotective agent against 
memory loss, both WT and GYSl-/-/tg mice were exposed to rotarod treadmill while 
hypoglycemic or euglycemic. The mice underwent four trials over a course of eight days 
on the rotarod. Blood glucose was taken prior to and immediately following rotarod 
exercise during trials 1 and 4, and taken prior to injection, 30 minutes following injection, 
60 minutes following injection, and immediately following rotarod during trials 2 and 3. 
Blood glucose was altered using insulin injections during trials 2 and 3 and consistently 
brought down to a range between 40-60mg/dl (figure 9). These levels are indicative of 
hypoglycemia, signifYing that 0.6U/kg for WT mice and 1.0 U/kg for GYSJ -I-Itg mice 
were sufficient levels of insulin to induce hypoglycemia within an hour of the time of 
injection. 
On average there was no difference in blood glucose levels in the two genotypes 
following trial 1 of the rotarod (figure 8). However, both genotypes experienced 
significantly higher blood glucose levels following rotarod when compared to the rested 
state, demonstrating the increased need for energy provided by glucose during times of 
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stress. This stress can be accounted for by both transportation into the experimental room 
from a separate room as well as the exposure to the rotarod machine in which the mice 
are learning new motor skills and having to exert energy to do so. Following rotarod 
assessment on the final trial, G YS 1-/-/tg mice had significantly higher blood glucose levels 
when compared to WT mice (figure 10). Because experimental procedures were 
consistent between both genotypes, these results insinuate that the increase in blood 
glucose following rotarod during trial 4 is due to the genetic alteration that results in 
overaccumulation of muscle glycogen in GYS 1-/-/tg mice. 
Hypoglycemic motor memory during level 7 (accelerating 3-30RPM) rotarod exposure 
During trial 1 of the experiment, there was no difference in latency between the 
two genotypes. The similarity in latency indicates that there is no difference between 
genotypes in balance and coordination (figure 13). The night prior to trials 2 and 3, mice 
were fasted in order to ensure they would reach hypoglycemic levels when injected with 
insulin. Consistent in both trials 2 and 3, saline treated G YS 1-/-/tg mice had similar latency 
as WT mice, while insulin treated GYS1-/-/tg and WT mice both had shorter latency on the 
rotarod (figure 13). The lack of difference in latency between saline treated WT and 
GYSl-/-/tg mice suggests equal learning capacity when it comes to motor skills regardless 
of brain glycogen levels. The significantly shorter latency in insulin treated groups when 
compared to saline treated groups indicates that motor skills are impaired during times of 
hypoglycemia. These results are consistent with clinical studies suggesting that learning 
in humans is compromised while blood glucose levels are low (Sommerfield 2003). 
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Mice were in a euglycemic state when exposed to the rotarod machine during trial 
4 to evaluate the level of learning that occurs while in the hypoglycemic state. WT mice 
that underwent the rotarod experiment while hypoglycemic during trials 2 and 3 had no 
difference in latency during trial 4 when compared to WT and GYS 1-/-/tg mice treated 
with saline during trials 2 and 3 (figure 13). GYS1 -/-/tg mice induced with hypoglycemia 
during trials 2 and 3 experienced significantly shorter latency when compared to saline 
treated WT and GYS 1-/-/tg mice as well as insulin treated WT mice. These results suggest 
a decreased capacity to learn new motor skills while in the hypoglycemic state without 
glycogen to serve as an emergency energy reservoir. There was no difference in latency 
between WT mice previously exposed to insulin-induced hypoglycemia and WT mice 
treated with saline. This evidence supports our hypothesis that glycogen is able to act as a 
neuroprotectant against memory loss and is able to provide an alternative energy source 
to glucose for neuronal activity. GYSrt-/tg mice lacking brain glycogen were unable to 
recover memory formed while in the hypoglycemic state, suggesting a lack of fuel 
needed to support the neuronal activity required for memory formation. Without a 
glycogen reservoir to supply alternative energy sources to the neurons, mice were unable 
to form memory of the motor skills learned while in insulin-induced hypoglycemia. 
Hypoglycemic motor memory during level 3 (consistent 28RPM) rotarod exposure 
In order to study the fast state of motor memory, mice were subjected to the 
rotarod at level 3, spinning at a constant 28RPM, following exposure to level 7 on the 
rotarod. This increased speed prevents the mice from "easing" into learning the motor 
skills required for the rotarod treadmill. The results seen concerning improvement in 
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rotarod performance across the four trials is comparable to the results of level 7 learning 
(figure 13). During trial 1, both WT and GYS 1-/-/tg mice preformed at a comparable level, 
resulting in similar latency to fall times. This result further supports the notion that motor 
skills can be developed at a parallel rate in mice containing brain glycogen and those null 
ofbrain glycogen (figure 14). During both trials 2 and 3, insulin treated WT and GYS1"1-
/tg mice had significantly reduced latency to fall times when compared to mice treated 
with saline, once again indicating motor skills are impaired during times ofhypoglycemia 
(figure 14). During trials 2 and 3, there was no difference in latency to fall times when 
comparing hypoglycemic WT mice to hypoglycemic GYS 1-/-/tg mice. Both genotypes of 
mice were equally impaired while under insulin-induced hypoglycemia, suggesting 
glycogen doesn't prevent motor skill impairment during hypoglycemic periods. 
During trial4 of the experiment, WT mice that experienced insulin-induced 
hypoglycemia during trials 2 and 3, had comparable latency as saline treated WT and 
GYS 1-/-/tg mice. The similar latency suggests that during the fast state of motor memory 
formation, glycogen plays a neuroprotective role against memory loss during periods of 
hypoglycemia. Unlike WT mice, GYS 1-/-/tg mice had significantly shorter latency to fall 
times than saline treated mice, indicating they were unable to recover memory formed 
during trials 2 and 3 when they were hypoglycemic. At both level 7 and level 3, mice 
lacking brain glycogen had significantly impaired latency times during trial 4. These 
results suggests a lack of memory formation, supporting the hypothesis that glycogen acts 
as a neuroprotective agent against memory loss and effectively assists in memory 
formation during insulin-induced hypoglycemia. 
39 
Lactate measurements 
Although the results support the hypothesis of glycogen's role as a 
neuroprotectant, exactly how this polymer assists in memory formation and recollection 
is still not clear. We hypothesized that substrates resulting from glycogenolysis, 
specifically lactate can be shuttled from astrocytes into neurons and used as an alternative 
energy source to glucose. Evidence supporting this hypothesis show that inhibiting lactate 
transport between brain cells by blocking the MCT induction disrupts memory formation 
(Suzuki 2011). In order to test this hypothesis, we measured blood lactate prior to and 
immediately following rotarod exercise. Consistent throughout all four trials, blood 
lactate levels were significantly higher in GYS 1-/-/tg mice than in WT mice following 
exercise on the rotarod (figure 11). This is consistent with the increased levels of muscle 
glycogen within GYS 1-/-/tg mice being degraded to lactate during muscle contractions 
while walking on the rotarod. Although WT mice had lower levels of blood lactate than 
G YS 1-/-/tg mice, their blood lactate levels still increased significantly following rotarod 
when compared to lactate levels prior to exposure (table 1). The result that lactate is 
increasing in the blood following rotarod, could result in increased delivery of lactate 
from the blood to the brain, thus providing neurons with a substrate that can be converted 
into pyruvate and utilized in the TCA cycle to generate A TP required for memory 
formation. These results support the hypothesis that lactate may be utilized in the brain as 
an alternate to glucose during times of hypoglycemia and is consistent with papers 
indicating lactate is required for memory formation (Suzuki 2011). 
Western Blot Analysis: 
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In order to further investigate the role of brain glycogen as a neuroprotectant 
against memory loss, a western blot analysis was utilized to track protein expression in 
different regions of the brain. We hypothesized that mice lacking brain glycogen would 
show decreased levels of memory protein expression due to their lack of an alternative 
energy source to glucose that glycogen provides during hypoglycemia. The cerebellum, 
hippocampus, and cortex (figure 4) were all dissected approximately 24 hours following 
trial 4 of the rotarod experiment. The brains were than homogenized and blotted to 
analyze the expression of the motor protein KIF 1 7. Although expression of the protein 
has yet to shown to be directly affected by motor memory, it has been shown to be 
interconnected with other proteins that change in expression level following motor 
memory formation (Roberson 2008). The western blot resulted in bands at ~ 170kD, 
indicating the protein is expressed in the three regions of the brain. Expression of the 
protein was shown to be comparable across treatment groups and genotypes, however no 
conclusive evidence can be drawn from this as it was only duplicated a single time. More 
western blots analysis is needed to provide further evidence ofKIF17's expression during 
memory formation. 
Conclusion: 
Using the rotarod treadmill, we have shown that brain glycogen is not a required 
component for memory formation while in the euglycemic state, demonstrated by the 
equal performance of both WT and GYSr/-/tg mice across all four trials on the rotarod. 
Brain glycogen was shown to play an important role in memory formation and 
recollection during times of hypoglycemia as WT mice exposed to insulin induced 
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hypoglycemia preformed at a significantly higher rate during the last trial on the rotarod 
when compared to GYSr/-/tg mice previously exposed to insulin-induced hypoglycemia. 
These results suggest that WT mice have access to glycogen resivours within astrocytes 
during hypoglycemic periods and this glycogen improved motor memory formation when 
blood glucose is unavailable. The results from this experiment also suggest motor skills 
are significantly impaired during times of hypoglycemia, as seen by the significantly 
shorter latency in insulin treated groups as compared to saline treated groups. Analyzing 
the expression of KIF 1 7 in mice of differing brain glycogen levels provided no 
conclusive evidence into glycogen' s role as a neuroprotectant. 
Using blood glucose measurements, this experiment indicated the optimal dosage 
of insulin to bring WT and G YS r l-ltg mice down to hypoglycemic levels. It also indicated 
the overexpression of glycogen synthase G YS 1-/-/tg mice causes significantly higher blood 
glucose levels following times of stress when compared to WT mice. Lactate was also 
raised at a substantially higher rate in mice overexpressing muscle glycogen as evidenced 
by increased levels of blood lactate in G YS 1-/-/tg mice compared to WT mice. This lactate 
could act as a compensatory mechanism providing the energy production needed to 
support neuronal cell activity. 
Future directions: 
In order to better understand the role brain glycogen plays in motor memory 
formation, future rotarod experiments will be conducted using different models of mice. 
Due to the genetic makeup of G YS 1-/-/tg mice that leads to overaccumulation of muscle 
glycogen, the mice could be adapting to their physiological excess of muscle glycogen by 
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shuttling glycogenolytic substrates into the brain to be used as alternative energy source 
in neurons. A mouse model completely null of brain glycogen, but containing normal 
levels of muscle glycogen would be beneficial because similarity to WT mice concerning 
levels of glycogen outside of the central nervous system. 
Aside from a mouse model null of brain glycogen that contains normal glycogen 
levels outside of the CNS, other memory proteins could be analyzed using a western blot 
to evaluate glycogen' s role in memory formation. Proteins such as CREB, pCREB, and 
Arc have been demonstrated to be involved in motor memory formation, thus differing 
expression levels in a western blot analysis would provide insight into glycogen's role in 
memory formation. 
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